Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 6/20 | 0.36 |
| ▸ | THRB | P10828 | 6/20 | 0.36 |
| ▸ | OGG1 | O15527 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797473 | 0.88 | PHGDH (0.36) | PHGDH | |
| SCHEMBL6795651 | 0.86 | HPGD (0.41) | THRATHRBOGG1GALR3GAA | |
| SCHEMBL6795612 | 0.85 | LDHA (0.32) | GALR3GAA | |
| Bromide SCHEMBL6800194 | 0.85 | LDHA (0.31) | GALR3GAA | |
| SCHEMBL6798938 | 0.81 | MCL1 (0.37) | PHGDHLMNAMAPTMCL1 | |
| SCHEMBL7573183 | 0.81 | PGK1 (0.36) | SLC9A1PHGDHLMNAF2F10 | |
| SCHEMBL6794680 | 0.80 | PHGDH (0.34) | GALR3GAASLC9A1PHGDH | |
| SCHEMBL6804622 | 0.79 | THRA (0.33) | THRATHRBSLC9A1PHGDHLMNA | |
| SCHEMBL6800597 | 0.78 | FBP1 (0.35) | GALR3GAASLC9A1LMNAMAPT | |
| SCHEMBL6794685 | 0.78 | PHGDH (0.35) | SLC9A1PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734205-B2 | SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030018056-A1 | Substituted guanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1238971-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018056-A1 | Substituted guanidine derivatives | SLC28A1, SLC7A1, ABCB11 | THRA 2350/4885THRB 2239/4885OGG1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.